4.6 Article

A cost-effectiveness analysis of an in-hospital clinical pharmacist service

Journal

BMJ OPEN
Volume 2, Issue 1, Pages -

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/bmjopen-2011-000329

Keywords

-

Funding

  1. National Board of Health and Welfare

Ask authors/readers for more resources

Objective: A randomised controlled study performed from 2007 to 2008 showed beneficial effects of a composite clinical pharmacist service as regards a simple health status instrument. The present study aimed to evaluate if the intervention was cost-effective when evaluated in a decision-theoretic model. Design: A piggyback cost-effectiveness analysis from the healthcare perspective. Setting: Two internal medicine wards at Sahlgrenska University Hospital, Goteborg, Sweden. Participants: Of 345 patients (61% women; median age: 82 years; 181 control and 164 intervention patients), 240 patients (62% women, 82 years; 124 control and 116 intervention patients) had EuroQol-5 dimensions (EQ-5D) utility scores at baseline and at 6-month follow-up. Outcome measures: Costs during a 6-month follow-up period in all patients and incremental cost-effectiveness ratio per quality-adjusted life-year (QALY) in patients with EQ-5D utility scores. Inpatient and outpatient care was extracted from the VEGA database. Drug costs were extracted from the Swedish Prescribed Drug Register. A probabilistic analysis was performed to characterise uncertainty in the cost-effectiveness model. Results: No significant difference in costs between the randomisation groups was found; the mean total costs per individual +/- SD, intervention costs included, were (sic)10 748 +/- 13 799 (intervention patients) and (sic)10 344 +/- 14 728 (control patients) (p=0.79). For patients in the cost-effectiveness analysis, the corresponding costs were (sic)10 912 +/- 13 999 and (sic)9290 +/- 12 885. Intervention patients gained an additional 0.0051 QALYs (unadjusted) and 0.0035 QALYs (adjusted for baseline EQ-5D utility score). These figures result in an incremental cost-effectiveness ratio of (sic)316 243 per unadjusted QALY and (sic)463 371 per adjusted QALY. The probabilistic uncertainty analysis revealed that, at a willingness-to-pay of (sic)50 000/QALY, the probability that the intervention was cost-effective was approximately 0.2. Conclusions: The present study reveals that an intervention designed like this one is probably not cost-effective. The study thus illustrates that the complexity of healthcare requires thorough health economics evaluations rather than simplistic interpretation of data.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Health Care Sciences & Services

Nordic responses to Covid-19: Governance and policy measures in the early phases of the pandemic

Ingrid Sperre Saunes, Karsten Vrangbek, Haldor Byrkjeflot, Signe Smith Jervelund, Hans Okkels Birk, Liina-Kaisa Tynkkynen, Ilmo Keskimaki, Sigurbjorg Sigurgeirsdottir, Nils Janlov, Joakim Ramsberg, Cristina Hernandez-Quevedo, Sherry Merkur, Anna Sagan, Marina Karanikolos

Summary: This paper explores and compares health system responses to the COVID-19 pandemic in Denmark, Finland, Iceland, Norway, and Sweden. The findings suggest differences in implementation and outcomes despite similar policy measures adopted by these countries. Factors such as migrant populations and working conditions may play a role in the variations in outcomes. Additionally, the paper highlights the potential impact of the COVID-19 epidemic on legislation and governance principles in the Nordic countries.

HEALTH POLICY (2022)

Review Cardiac & Cardiovascular Systems

Efficacy and Safety of Clopidogrel Versus Ticagrelor as Part of Dual Antiplatelet Therapy in Acute Coronary Syndrome-A Systematic Review and Meta-analysis

Niklas Bergh, Anna Myredal, Per Nivedahl, Max Petzold, Sultan Zarin, Constanze Wartenberg, Susanna M. Wallerstedt

Summary: This review compares the efficacy and safety of clopidogrel and ticagrelor as part of dual antiplatelet therapy in patients with acute coronary syndrome and older patients. The results show that there is little or no difference in all-cause mortality between the two drugs. Although not evident in older patients, it cannot be excluded that clopidogrel may be slightly less efficient in reducing the risk of cardiovascular mortality and myocardial infarction, whereas ticagrelor is probably more efficacious in reducing the risk of stent thrombosis. Clopidogrel results in a reduced risk of dyspnea and clinically significant bleeding, and in older people probably in a reduced risk of major bleeding.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2022)

Article Pharmacology & Pharmacy

Drug interaction alerts in older primary care patients, and related medically justified actions

Carina Tukukino, Naldy Parodi Lopez, Staffan A. Svensson, Susanna M. Wallerstedt

Summary: This study described the interaction alerts in older patients and evaluated whether these alerts required further medical action or had already been addressed. The results showed that most alerts had already been addressed or were not relevant in the clinical setting, but some patients still needed medical action.

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2022)

Article Pharmacology & Pharmacy

Clinical relevance of potentially inappropriate medications and potential prescribing omissions according to explicit criteria-a validation study

Naldy Parodi Lopez, Staffan A. Svensson, Susanna M. Wallerstedt

Summary: This study investigates the clinical relevance of potentially inappropriate medications (PIMs) and potential prescribing omissions (PPOs), and finds that a fraction of them are clinically relevant. The study shows that the number of PIMs/PPOs and the number of drugs are associated with inadequate drug treatment.

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2022)

Article Pharmacology & Pharmacy

Prevalence and initiation of statin therapy in the oldest old-a longitudinal population-based study

Helena Sundvall, Sigurd Vitols, Susanna M. Wallerstedt, Johan Fastbom

Summary: The prevalence and initiation of statin therapy are increasing among the oldest old, despite the lack of randomized controlled trials focusing on this age group and the difficulty in detecting safety signals.

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2022)

Article Pharmacology & Pharmacy

Revisiting the inter-rater reliability of drug treatment assessments according to the STOPP/START criteria

Naldy Parodi Lopez, Bjorn Belfrage, Anders Koldestam, Johan Lonnbro, Staffan A. Svensson, Susanna M. Wallerstedt

Summary: This study aimed to revisit the inter-rater reliability of drug treatment assessments according to the STOPP/START criteria. The findings showed issues with reliability and highlighted methodological factors that may contribute to inconsistency.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2023)

Article Medicine, General & Internal

Performance of 3 Sets of Criteria for Potentially Inappropriate Prescribing in Older People to Identify Inadequate Drug Treatment

Susanna M. Wallerstedt, Staffan A. Svensson, Johan Lonnbro, Fredrik Hieronymus, Johan Fastbom, Mikael Hoffmann, Naldy Parodi Lopez

Summary: In this diagnostic study, the evaluated PIM/PPO sets had poor to fair performance as diagnostic tools to identify inadequate drug treatment, suggesting the need for reconsideration of using PIMs/PPOs as indicators of drug treatment quality.

JAMA NETWORK OPEN (2022)

Article Pharmacology & Pharmacy

Interaction alerts: A comparison of classifications and recommendations for clinical management between Janusmed and three other knowledge resources

Carina Tukukino, Anna L. Eriksson, Walaa Hamdan, Frida Wallin Hybelius, Susanna M. Wallerstedt

Summary: Classifications of drug interaction alerts vary between knowledge resources, but there is limited exploration of agreement in recommendations for clinical management. A study analyzed medication lists of 274 older patients and found that while many drug pairs triggered alerts of similar significance in different resources, the recommendations provided varied considerably. The findings highlight the need for medical and pharmaceutical reflection on prescribing decisions as the recommendations cannot be considered definitive.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2023)

Article Pharmacology & Pharmacy

Drug information sources in professional work-a questionnaire study on physicians' usage and preferences (the drug information study)

Pia Seidel, Bo Rolander, Anna L. Eriksson, Ulf Lindahl, Susanna M. Wallerstedt, Staffan Haegg, Anders Kling

Summary: This study aimed to investigate the use of drug information by physicians in their professional work, particularly those working in primary care. A web-based questionnaire was distributed to physicians in Sweden, addressing drug-related queries, sources used, and factors influencing source choice. The study found that physicians frequently use drug information sources, especially those in primary care. Credibility and easy access were key factors influencing source choice, and personal characteristics also influenced the choice of drug information sources in primary care.

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2023)

Article Clinical Neurology

Validation of the Swedish Patient-Reported Outcomes in Parkinson's Disease Scale in Outpatients

Daniel von Below, Susanna M. Wallerstedt, Filip Bergquist

Summary: This study aimed to validate the Patient-Reported Outcomes in Parkinson's Disease (PRO-PD) scale for monitoring symptoms in PD patients. The results showed that PRO-PD exhibited good reliability and validity in monitoring symptoms in a representative sample of outpatients with PD.

MOVEMENT DISORDERS (2023)

Meeting Abstract Public, Environmental & Occupational Health

Clinically significant drug interaction alerts in older patients, and related medically justified action

Staffan A. Svensson, Carina Tukukino, Naldy Parodi Lopez, Susanna M. Wallerstedt

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2022)

Meeting Abstract Public, Environmental & Occupational Health

Agreement between interaction alerts in different sources regarding classification and suggested clinical management

Carina Tukukino, Walaa Hamdan, Frida Wallin Hybelius, Anna L. Eriksson, Susanna M. Wallerstedt

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2022)

Meeting Abstract Public, Environmental & Occupational Health

Performance of three sets of criteria for potentially inappropriate prescribing as diagnostic tools to identify inadequate drug treatment

Susanna M. Wallerstedt, Johan Lonnbro, Staffan A. Svensson, Fredrik Hieronymus, Johan Fastbom, Mikael Hoffmann, Naldy Parodi Lopez

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2022)

Meeting Abstract Public, Environmental & Occupational Health

Assessments of potential adverse drug reactions according to a trigger tool-A descriptive analysis

Johan Lonnbro, Lina Holmqvist, Elisabeth Persson, Per Thyzell, N. David Aberg, Susanna M. Wallerstedt

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2022)

Meeting Abstract Public, Environmental & Occupational Health

Drug treatment in older patients according to indicators of potentially rational prescribing

Naldy Parodi Lopez, Staffan A. Svensson, Susanna M. Wallerstedt

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2022)

No Data Available